The global high content screening market is expected to witness lucrative market growth as a consequence of the rising need for the development of new drug molecules owing to the presence of obsolete drug therapies with less potency. The increasing need is also attributed to the rising prevalence of chronic diseases requiring intensive treatment such as HIV AIDS, epilepsy, and Parkinson’s disease. The rising need for determination and study of toxicity levels in the initial phases of drug discovery is also a high impact rendering driver for the market. Technological advancements including usage of multicolored fluorescence-based reagents, polarization techniques, automated imaging technology, and flow cytometry are anticipated to drive the market growth further. With the advent of these advancements, unwanted toxicities during drug interactions are eliminated. This leads to an increase in the stability of new drugs, greater accuracy, reduction in drug discovery time, and increased cost efficiency and hence is expected to further boost the demand for the market. Moreover, better data visualization tools, improved software, and new detection methods such as fluorescence lifetime & multispectral imaging are predicted to drive growth. Furthermore, benefits associated with these innovations such as application in gene identification & neonatal development studies and enhanced penetrability of drugs are anticipated to provide growth potential to the market over the forecast period.
The global high content screening market is segmented on the basis of product, end use, and application. On the basis of product, it is segregated into consumables, microplates, instruments, software, and service. On the basis of application, it is categorized into primary & secondary screening, compound profiling, and target identification & validation. On the basis of end-use, it is segmented into contract research organizations, pharmaceutical & biotechnology companies, and academic and research institutes. As of 2014, the high screening instrument segment held a substantial share in this market owing to the need for high cost-efficient alternatives. The cost efficiency is resultant from the employment of features such as LED light engines that reduces the intensity fluctuations and hence eliminates the need of switching onto external illuminating sources. Advancements in this segment such as the adoption of filter sets, auto-focus methods, and efficient illuminating sources also played a significant part in inducing overall growth. The high content screening software segment is expected to be the fastest-growing segment over the forecast period owing to features like confocal imaging and intuitive workflow interface. This thereby results in the development of three-dimensional models allowing better evaluation, increased sensitivity precise image capture, and analyzation of more parameters which is expected to boost the demand for the market over the forecast period.
Geographically, the high content screening market is segregated into North America, Europe, Asia Pacific, Latin America, and MEA. As of 2014, North America held the largest share of the market owing to significant growth factors including increasing incidences of chronic diseases, rising prevalence of geriatric population, various collaborations with research institutes, high disposable income, and advanced healthcare infrastructure. Furthermore, the rising number of mergers & acquisitions and increased awareness also propelled the market growth in this region. It is followed by Europe which owing to factors such as high healthcare investments and government regulations in the region. Asia Pacific is anticipated to be the fastest-growing market over the forecast period as a consequence of prominent factors such as rising disposable income, increasing need for novel drugs, increasing patient awareness about the technologies integrated with improving healthcare infrastructure. Furthermore, new market entrants owing to less competition are expected to play an important role in providing a growth platform to the high content screening market in this region over the next seven years.
Major players of high content screening market are Molecular Devices, Thermo Fisher Scientific, PerkinElmer Inc., Becton, GE Healthcare, Dickinson and Company, Merck KGaA, Cell Signaling Technology, Thorlabs, Inc., Genedata AG, and Yokogawa Electric Corporation. These companies focus on unmet needs, aiming at developing novel technologies, geographic focus, mergers & acquisitions in order to expand their market share. Moreover, weak competition in the market is anticipated to provide growth potential new entrants in the market over the forecast period.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."